JPRN-jRCTs051180092已完成2 期
Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with nivolumab - Serum soluble PD-L1 and nibolumab in patients with renal cell carcinoma
akano Yuzo0 个研究点目标入组 43 人开始时间: 2019年3月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
研究概览
简要总结
In the present study, it was indicated that sPD-L1 may be a predictor of treatment response to nivolumab for metastatic renal cell carcinoma patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Advanced renal cell carcinoma
- •(2) metastatic and/or unresectable renal cell carcinoma
- •(3) 20 years old and more at informed consent
- •(4) Consent of the patient himself
- •(5) Patients who neeed 2nd-line therapy after the failure of 1st-line therapy or discontinuation due to adverse effect
排除标准
- •(1) The history of active cancer other than kidney
- •(2) Pregnant women (including the possibility) or lactating women
- •(3) The history of psychiatric disorder (therefore difficult of participation of this study)
- •(4) The history of allergic reaction caused by component of nivolumab
- •(5) patients who doctors assosiated of this study decided not to be applicable for this study because of other reasons
研究者
相似试验
已完成
不适用
Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with Nivolumabadvanced renal cell carcinomaJPRN-UMIN000027873Kobe University Graduate School of Medicine48
Unknown
不适用
Effect of Chemotherapy on PD-L1 in NSCLCChemotherapyImmunotherapyPD-L1NCT03701607Baodong Qin30
已完成
不适用
A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC PatientsNon Small Cell Lung CancerNCT04312308Yonsei University100
已完成
不适用
Preliminary study detecting of plasma soluble PD-L1 in the patients with advanced lung cancerlung cancerJPRN-UMIN000014760Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital96
已完成
不适用
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC PatientsNon -Small Cell Lung CancerNCT03486119Yonsei University60